BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration
Profluent’s new collaboration with BioMarin Pharmaceutical (BMRN) puts AI designed enzyme therapies at the center of the biotech group’s research effort, with BioMarin screening AI generated candidates for its rare disease pipeline.
For investors watching the tape, BioMarin Pharmaceutical’s share price has softened recently, with a 7 day share price return of 3.55% down and a 30 day share price return of 8.02% down, even as the 1 year total shareholder return of 9.37% sits in positive territory and the 3 year total shareholder return of 30.15% down shows how sentiment has cooled over a longer stretch.
Scan how AI focused drug developers are priced by reviewing the hand picked 36 healthcare AI stocks alongside BioMarin Pharmaceutical after this Profluent collaboration news.
After BioMarin Pharmaceutical’s recent pullback, yet still positive 1 year return, the key question is straightforward: has most of the rerating already played out, or does the current valuation still leave meaningful upside on the table?
Most Popular Narrative: 34.5% Undervalued
Against BioMarin Pharmaceutical’s last close of $60.00, the most followed narrative points to a fair value near $91.62. This frames the recent pullback as only part of a larger rerating story tied to portfolio scale and capital efficiency.
Focus previously sat on individual products and rare disease demand as the main revenue driver. Now it is on BioMarin Pharmaceutical scaling a broader multi asset rare disease portfolio and aiming to lift capital efficiency through acquisitions and cost synergies.
See why 41 investors see BioMarin Pharmaceutical as 35% undervalued.
Result: Fair Value of $91.62 (UNDERVALUED)
Still, the BioMarin Pharmaceutical story can change quickly if margins stay stuck near recent levels or if acquisitions like Amicus and Alesta fail to deliver the expected cost synergies.
Find out about the key risks to this BioMarin Pharmaceutical narrative.
Next Steps
Mixed messages in the BioMarin Pharmaceutical story so far. Investors may wish to act quickly, review both sides of the data, and weigh the 3 key rewards and 4 important warning signs.
Looking for more investment ideas beyond BioMarin Pharmaceutical?
If BioMarin Pharmaceutical has your attention, do not stop here. Use the Simply Wall Street Screener to uncover fresh opportunities that might better fit your portfolio.
- Target companies that trade below their assessed worth and see whether any on the 31 high quality undervalued stocks match the quality and pricing mix you want.
- Prioritise resilience and sleep easier at night by reviewing the 31 resilient stocks with low risk scores that score well on stability and risk controls.
- Spot lesser known opportunities with solid fundamentals and growth potential by scanning the 19 high quality undiscovered gems before attention and liquidity move elsewhere.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com